Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Mach7 Technologies ( (AU:M7T) ).
Mach7 Technologies reported a strong financial performance for FY25, with a 16% increase in total revenue to A$33.8M, driven by a 20% rise in recurring revenue. The company achieved a positive operating cash flow and improved its EBITDA significantly, reflecting strong revenue growth and cost control. With A$23.1M in cash and no debt, Mach7 is well-positioned for future growth. The company plans to focus on refining its customer model and expanding its global footprint to enhance customer support and R&D capabilities, particularly in North America.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies Limited specializes in innovative medical imaging software solutions, focusing on enhancing healthcare delivery through advanced imaging technologies.
Average Trading Volume: 269,782
Technical Sentiment Signal: Sell
Current Market Cap: A$77.54M
For a thorough assessment of M7T stock, go to TipRanks’ Stock Analysis page.